Literature DB >> 26643345

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.

Paolo Denti1, Neil Martinson2, Silvia Cohn3, Fildah Mashabela4, Jennifer Hoffmann3, Reginah Msandiwa4, Sandra Castel1, Lubbe Wiesner1, Richard E Chaisson3, Helen McIlleron1, Kelly E Dooley5.   

Abstract

Effective treatment of tuberculosis during pregnancy is essential for preventing maternal and fetal mortality, but little is known about the effects of pregnancy on the disposition of antituberculosis drugs. We explored the effects of pregnancy on the pharmacokinetics of rifampin, the key sterilizing drug in tuberculosis treatment, in Tshepiso, a prospective cohort study involving pregnant HIV-infected women with or without tuberculosis in Soweto, South Africa. Participants receiving standard first-line tuberculosis treatment underwent sparse sampling for rifampin at 37 weeks' gestation or delivery and then postpartum. Cord blood was collected when possible. A population pharmacokinetic model was developed to investigate the effects of pregnancy on rifampin pharmacokinetics. Among the 48 participants, median age and weight were 28 years and 67 kg, respectively. A one-compartment model with first-order elimination, transit compartment absorption, and allometric scaling described the data well. Pregnancy reduced rifampin clearance by 14%. The median (interquartile range) model-estimated rifampin area under the concentration-time curve over 24 h (AUC0-24) during pregnancy or intrapartum was 40.8 h · mg/liter (27.1 to 54.2 h · mg/liter) compared to 37.4 h · mg/liter (26.8 to 50.3 h · mg/liter) postpartum. The maximum concentrations were similar during pregnancy and postpartum. Rifampin was detectable in 36% (8/22) of cord blood samples, and 88% (42/48) of the women had successful treatment outcomes. There was one case of perinatal tuberculosis. In conclusion, rifampin clearance is modestly reduced during the last trimester of pregnancy. Exposures are only slightly increased, so dose adjustment during pregnancy is not needed. Rifampin was detected in cord blood samples when delivery occurred soon after dosing. The consequences of exposure to this potent inducer of metabolizing enzymes among HIV-exposed infants are unclear.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26643345      PMCID: PMC4776013          DOI: 10.1128/AAC.02051-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

2.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

Review 3.  Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks.

Authors:  Gerard G Nahum; Kathleen Uhl; Dianne L Kennedy
Journal:  Obstet Gynecol       Date:  2006-05       Impact factor: 7.661

4.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

5.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 6.  Exclusion of pregnant women from industry-sponsored clinical trials.

Authors:  Kristine E Shields; Anne Drapkin Lyerly
Journal:  Obstet Gynecol       Date:  2013-11       Impact factor: 7.661

Review 7.  Variation of drug kinetics in pregnancy.

Authors:  Petr Pavek; Martina Ceckova; Frantisek Staud
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.

Authors:  Kidola Jeremiah; Paolo Denti; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

10.  High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa.

Authors:  Christopher J Hoffmann; Ebrahim Variava; Modiehi Rakgokong; Katlego Masonoke; Martin van der Watt; Richard E Chaisson; Neil A Martinson
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more
  15 in total

1.  Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.

Authors:  Gene D Morse
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Anti-Tubercular Drugs in Pregnancy.

Authors:  Jennifer R Shiu; Alan Min; Tony K L Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

3.  Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.

Authors:  Mahmoud Tareq Abdelwahab; Rory Leisegang; Kelly E Dooley; Jyoti S Mathad; Lubbe Wiesner; Helen McIlleron; Neil Martinson; Ziyaad Waja; Matebogo Letutu; Richard E Chaisson; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.

Authors:  Helen McIlleron; Paolo Denti; Silvia Cohn; Fildah Mashabela; Jennifer D Hoffmann; Saba Shembe; Regina Msandiwa; Lubbe Wiesner; Sithembiso Velaphi; Sanjay G Lala; Richard E Chaisson; Neil Martinson; Kelly E Dooley
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 6.  Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

Authors:  Vera E Bukkems; Angela Colbers; Catia Marzolini; Jose Molto; David M Burger
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

7.  Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.

Authors:  Andreas Diacon; Sachiko Miyahara; Rodney Dawson; Xin Sun; Evelyn Hogg; Kathleen Donahue; Michael Urbanowski; Veronique De Jager; Courtney V Fletcher; Richard Hafner; Susan Swindells; William Bishai
Journal:  Lancet Microbe       Date:  2020-06-08

8.  Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.

Authors:  Amita Gupta; Michael D Hughes; Anthony J Garcia-Prats; Katherine McIntire; Anneke C Hesseling
Journal:  PLoS Med       Date:  2019-08-15       Impact factor: 11.069

Review 9.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12

Review 10.  Current research toward optimizing dosing of first-line antituberculosis treatment.

Authors:  Helen McIlleron; Maxwell T Chirehwa
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-12       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.